基于TNF-α信号转导通路蒙药给旺-9对非酒精性脂肪性肝病作用机制的研究

Research used currently more recognized of method established Non-alcoholic Fatty liver disease rat model, on fat metabolism and TNF- a pathway for Mongolian Medication GiWang-9 regulation rat non-alcoholic Fatty liver disease of molecular mechanism research, focus research SREBP-1c and TNF-a of correlation, stated Mongolian Medication GiWang-9 treatment non-alcoholic Fatty liver disease of role target points, revealed Mongolian Medication GiWang-9 on TNF-a pathway regulation of mechanism, Comparison to Mongolian Medication GiWang-9 and the positive control drug Rosiglitazone on non-alcoholic fatty liver disease of difference, for clinical application of Mongolian Medication GiWang-9 and non-alcoholic steatohepatitis (NASH) provide the scientific basis of clinical treatment.

研究采用目前较为公认的方法建立非酒精性脂肪性肝病大鼠模型，对脂代谢与TNF-α通路进行蒙药给旺-9调控大鼠非酒精性脂肪性肝病的分子机制研究，重点研究大鼠固醇调节元件结合蛋白-1c（SREBP-1c)与TNF-α的相关性，阐明蒙药给旺-9治疗非酒精性脂肪性肝病的作用靶点，揭示蒙药给旺-9对TNF-α通路调控的机制，比较蒙药给旺-9与阳性对照药罗格列酮治疗非酒精性脂肪性肝病的作用差异，为蒙药给旺-9的临床运用及非酒精性脂肪性肝炎（NASH）的临床治疗提供科学依据。

研究采用目前较为公认的方法建立非酒精性脂肪性肝病大鼠模型，对脂代谢与TNF-α通路.进行蒙药给旺-9调控大鼠非酒精性脂肪性肝病的分子机制研究，重点研究大鼠固醇调节元.件结合蛋白-1c（SREBP-1c)与TNF-α的相关性，阐明蒙药给旺-9治疗非酒精性脂肪性肝病.的作用靶点，揭示蒙药给旺-9对TNF-α通路调控的机制，比较蒙药给旺-9与阳性对照药罗.格列酮治疗非酒精性脂肪性肝病的作用差异，为蒙药给旺-9的临床运用及非酒精性脂肪性.肝炎（NASH）的临床治疗提供科学依据。